% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • tempestdog743 tempestdog743 Nov 1, 2012 5:54 PM Flag

    Use off-label of Kyprolis?

    Given the fact that Kyprolis causes significantly less peripheral neuropathy (12 percent vs competition's 43 percent), is there a chance that oncologists will use off-label and not withhold treatment as a third-line option? Are there physicians on this board qualified to have an opinion in this regard?

    Sentiment: Strong Buy